Novartis 2019 Financial Results

Download the media release
English (PDF 0.1 MB )  |  Deutsch (PDF 0.1 MB)  |  Français (PDF 0.1 MB)

Condensed financial report (PDF 0.7 MB) …

/by

Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019

  • Full year net sales for continuing operations1 up 9% (cc2, +6% USD):
    • Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and Zolgensma USD 361 million
    • Oncology BU growing 10% (cc) driven by Promacta/Revolade USD 1.4 billion (+23% cc), Kisqali USD 0.5 billion (+111% cc) and Lutathera USD 0.4 billion (+160% cc)
    • Sandoz sales grew 2% (cc, -1% USD) driven by Biopharmaceuticals …
/by